AOD-9604 in Purac — Fat Loss Peptide Research Guide
AOD-9604 research guide for Purac. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
The pursuit for AOD-9604 in Purac inevitably reaches the same conclusion: research peptides are distributed through specialist online vendors, not local pharmacies. This matters because AOD-9604 quality differs enormously across the market — from analytically confirmed high-purity product to material with significant impurity issues — and the vendor controls every quality variable. What reliably differentiates top AOD-9604 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety documentation. This guide gives Purac researchers the practical tools to assess vendor quality rigorously and source verified-quality AOD-9604 with confidence.
Understanding AOD-9604 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Purac comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying AOD-9604: Quality Markers to Look For
Assessing AOD-9604 vendors requires starting from the COA: access the batch-specific certificate prior to buying, not after. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from bacterial cell wall components can trigger dangerous inflammatory cascades even at trace quantities. The combination of community reputation data and your own COA analysis is the most effective quality filter — community feedback surfaces recurring issues no single purchase reveals, and vice versa. Store lyophilised AOD-9604 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order AOD-9604 — ships to Purac
COA-verified · International tracking · Research grade
AOD-9604 is supplied strictly for research applications and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is educational. Storage requirements for AOD-9604: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. Quality AOD-9604 sourcing is inseparable from safety — bacterial endotoxin contamination, mislabeling, and degradation products are all safety issues that proper COA verification addresses. Protocol documentation — keeping clear records of compound, timing, and method — is a sound practice for any AOD-9604 protocol that ensures unusual findings can be explained.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
